Compare Salesforce Inc (CRM) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Quest Diagnostics Inc — how do they compare? Salesforce Inc trades at $193.4 (market cap $161.73B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Salesforce Inc is far larger — about 6.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| CRM | DGX | |
|---|---|---|
Market Cap | $161.73B | $26.21B |
Sector | Technology | Health |
52-Week High | $266.23 | $238.50 |
52-Week Low | $150.12 | $173.49 |
Enterprise Value | $191.77B | $31.97B |
Dividend Yield | 0.89% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $192.33, down 2.62% amid broader software sector weakness driven by AI disruption concerns. The stock maintains strong fundamentals with consistent earnings beats, 77.64% gross margins, and 18.73% net income margin. Technical indicators show bullish momentum despite overbought RSI readings, with key support at $193. Analyst consensus remains strongly bullish with a $230.83 price target representing 20% upside potential.
CRM presents a compelling investment case with robust profitability, AI monetization growth, and discounted valuation. Near-term risks include software sector volatility and AI competition, but strong cash flow generation and institutional support provide stability. The current dip offers entry opportunity for long-term investors seeking exposure to enterprise software leadership.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
